One product
A defined healthcare technology or system under evaluation.
Clinical Adoption Intelligence
Know what must be true before clinicians and institutions can adopt your product.
For one healthcare product in one country, GHMAP investigates relevant clinician and institutional evidence to surface barriers, conditions, disagreement, and unresolved uncertainty before launch or expansion.
Product model
One commercial unit. One adoption decision.
GHMAP investigates clinical and institutional barriers for a locked decision scope — not a generic consulting engagement.
One country
A single market context for clinical and institutional conditions.
One clinical use case
The care setting and workflow where adoption must succeed.
One adoption decision
A clear management question about barriers and conditions for adoption.
Product
One defined healthcare product
Country
One target country
Adoption decision
One clinical use case + one adoption decision
Why clinician opinion alone is incomplete
Clinical value does not automatically become adoption.
A positive clinical reaction still leaves workflow fit, implementation feasibility, institutional sponsorship, and purchase feasibility unresolved.
Clinical value
Perceived usefulness does not automatically establish workflow fit.
Workflow fit
Fit still leaves implementation feasibility unresolved.
Implementation feasibility
Technical readiness does not create institutional sponsorship.
Purchase feasibility
Sponsorship alone does not confirm ownership, governance, or procurement conditions.
Who must be heard
Four evidence contributions — not a network map.
Each category exists because it contributes different evidence to the adoption decision.
Clinical Users
How the product is used in practice, where it helps or disrupts workflow, and which competencies are required.
Clinical / Scientific Influencers
Evidence expectations, peer norms, governance pressure, and conditions that shape clinical acceptability.
Implementation & Technical
Integration, training load, IT/clinical engineering constraints, and operational feasibility.
Institutional / Economic
Sponsorship, budget ownership, procurement pathways, and institutional conditions for purchase or deployment.
Clinical Users
How the product is used in practice, where it helps or disrupts workflow, and which competencies are required.
Clinical / Scientific Influencers
Evidence expectations, peer norms, governance pressure, and conditions that shape clinical acceptability.
Implementation & Technical
Integration, training load, IT/clinical engineering constraints, and operational feasibility.
Institutional / Economic
Sponsorship, budget ownership, procurement pathways, and institutional conditions for purchase or deployment.
What GHMAP investigates
Decision-relevant areas only.
Investigation concentrates on conditions that change the adoption decision — not an equal-weight wall of topics.
Clinical role
Where the product sits in care and who must trust it.
Workflow
How existing pathways absorb, resist, or reshape use.
Evidence expectations
What evidence stakeholders require before reliance.
Training
Competency, credentialing, and learning burden.
Implementation
Technical and operational conditions for reliable use.
Ownership
Who sponsors, budgets, governs, and maintains the capability.
Institutional conditions
Procurement, policy, and organizational constraints.
Adoption barriers
Where disagreement, friction, or missing conditions concentrate.
Evidence → Decision
Participant evidence becomes decision implication without erasing disagreement.
This chain is a core GHMAP trust mechanism: evidence, synthesis, interpretation, and implication remain separable.
01
Participant Evidence
Structured qualitative evidence from defined stakeholder strata.
02
GHMAP Synthesis
Patterns, contradictions, and evidence weight are assembled without averaging disagreement.
03
GHMAP Interpretation
Decision-relevant meaning is separated from raw participant statements.
04
Decision Implication
Management implications and conditions are stated with explicit limitations.
Real secondary context
Locked Türkiye secondary context for orientation only.
Synthetic primary-research demonstration
Explicitly synthetic participant-derived examples. IDs begin with SYN-.
GHMAP synthesis / interpretation
Decision-relevant patterns without averaging contradictions.
Decision implication
Conditions, barriers, or insufficient evidence stated with limitations.
Contradiction
Disconnected expert calls leave contradictions unresolved.
Disconnected expert calls can collect opinions without comparing them against governance, implementation, and ownership conditions.
Perspective A
A clinical user may report high perceived value in a specific acute setting.
Perspective B
An institutional or governance stakeholder may withhold sponsorship until ownership, training, and accountability are defined.
Training / governance bridge
Without structured comparison across strata, teams hear enthusiasm and blockers as separate stories — not as one adoption decision.
Management question: Which conditions must be true before clinical interest can become institutional adoption?
What the client receives
Four outputs. No public pricing.
Deliverables are decision artifacts — not a dashboard product or expert marketplace.
Output 01
Executive Adoption Decision Summary
A management-facing statement of barriers, conditions, disagreement, and remaining uncertainty.
Output 02
Clinical Adoption Intelligence Report
Decision-structured findings with evidence layers, contradictions, and implications.
Output 03
Research Evidence Workbook
Traceable finding rows linking evidence layer, theme, implication, and limitation.
Output 04
Executive Debrief
A working review of what the evidence supports, what it does not, and what to validate next.
Research boundaries
Qualitative research identifies conditions. It does not predict adoption percentages.
This research can identify
- Barriers
- Conditions
- Disagreement
- Evidence requirements
- Unresolved uncertainty
It does not by itself predict
- National adoption percentage
- Sales outcomes
- Market share
- Commercial success
Clinical access
Who can reach and operate the portable system in acute-care or cardiac-assessment settings.
Clinical governance
Who may interpret, who remains accountable, and which supervision rules apply.
Signature finding pattern (CAI-GOV-01): access interest can exist while governance remains unresolved.
AI CAPABILITY FRAMEWORK FOR RESEARCH — NOT A CLAIM ABOUT THE ILLUSTRATIVE PRODUCT
Level 01
Acquisition Guidance
Level 02
Image Quality Guidance
Level 03
Automated Measurement
Level 04
Clinical Interpretation
Level 05
Automated Reporting
Türkiye demonstration
Portable AI-enabled cardiac ultrasound. One country. One adoption decision.
Explore how GHMAP separates real secondary context, synthetic primary-research demonstration, and GHMAP interpretation.
REAL SECONDARYSYNTHETIC PRIMARY-RESEARCH DEMONSTRATION — NOT REAL PARTICIPANT DATAGHMAP INTERPRETATIONINSUFFICIENT EVIDENCE
Methodology / trust
Progressive disclosure of research discipline.
Internal SOPs are not published. Public methodology explains selection, verification, traceability, limitations, anonymization, and compliance principles.
Stakeholder selectionStrata are defined by evidence contribution to the locked adoption decision.
Participants are selected for role relevance to clinical use, governance, implementation, and institutional conditions — not for network size or marketing optics.
VerificationClaims are weighed against role context and secondary market context.
GHMAP separates what a participant reports from what secondary evidence can corroborate, and marks insufficient evidence explicitly.
Evidence traceabilityFindings remain linked to evidence layer and source identifiers.
Real secondary context, synthetic demonstration content, and GHMAP interpretation are labeled as distinct layers.
Qualitative limitationsQualitative research explains conditions and disagreement; it does not estimate adoption rates.
Sample composition is illustrative of decision coverage, not statistical representation of a national clinician population.
AnonymizationParticipant identities are protected in delivery.
Public demonstration content uses synthetic IDs only. No real clinician or hospital stakeholder is presented as interviewed for the sample.
Compliance principlesMarket-access decision support with professional review required.
GHMAP does not provide clinical decision support, regulatory approval, reimbursement guarantees, or market-entry guarantees.
GHMAP does not provide diagnosis, treatment advice, legal advice, regulatory approval, reimbursement guarantees, investment advice, or market-entry guarantees.
Request a Proposal
Tell GHMAP the product, country, and adoption decision.
Short form only. No public pricing. Fit review comes before any research intake or commercial underwriting discussion.
Next step
Request a Clinical Adoption Intelligence proposal
One product. One country. One clinical use case. One adoption decision.
No public pricing.